No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis

Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. doi: 10.1016/j.bbmt.2006.07.010.
No abstract available

Publication types

  • Letter

MeSH terms

  • Amino Acid Substitution*
  • Biomarkers
  • Hematopoietic Stem Cell Transplantation / statistics & numerical data*
  • Humans
  • Janus Kinase 2 / genetics*
  • Janus Kinase 2 / physiology
  • Kaplan-Meier Estimate
  • Mutation, Missense*
  • Point Mutation*
  • Polycythemia Vera / enzymology
  • Polycythemia Vera / genetics*
  • Polycythemia Vera / mortality
  • Polycythemia Vera / surgery
  • Primary Myelofibrosis / enzymology
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / mortality
  • Primary Myelofibrosis / surgery
  • Prognosis
  • Recurrence
  • Risk
  • Survival Analysis
  • Thrombocythemia, Essential / enzymology
  • Thrombocythemia, Essential / genetics*
  • Thrombocythemia, Essential / mortality
  • Thrombocythemia, Essential / surgery
  • Transplantation, Homologous / statistics & numerical data
  • Treatment Outcome

Substances

  • Biomarkers
  • Janus Kinase 2